Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PDE2A | O00408 | 4/20 | 0.49 |
| ▸ | BRD4 | O60885 | 9/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12729942 | 0.90 | PDE2A (0.48) | ALDH1A1PDE2ABRD4MAOAMAOB | |
| SCHEMBL12672081 | 0.84 | PDE2A (0.47) | PDE2AMAOAMEN1KMT2A | |
| SCHEMBL1599384 | 0.73 | TYMS (0.71) | ALDH1A1PDE2ANPC1RAB9AMAOA | |
| SCHEMBL21642450 | 0.71 | BRD4 (0.71) | BRD4 | |
| SCHEMBL21642605 | 0.69 | BRD4 (0.66) | BRD4 | |
| SCHEMBL14431653 | 0.68 | IKBKB (0.81) | — | |
| SCHEMBL21642226 | 0.67 | BRD4 (0.78) | BRD4 | |
| SCHEMBL20440364 | 0.67 | BRD4 (0.78) | BRD4 | |
| SCHEMBL20440365 | 0.67 | BRD4 (0.66) | BRD4 | |
| SCHEMBL4309941 | 0.66 | KDM4E (0.39) | ALDH1A1NPC1GAARAB9AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | ALDH1A1 802/4885PDE2A 811/4885BRD4 2095/4885 |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | ALDH1A1 802/4885PDE2A 811/4885BRD4 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.